AI Article Synopsis
Article Abstract
Antibodies against polyethylene glycol (PEG) in healthy subjects raise concerns about the efficacy of pegylated drugs. We evaluated the prevalence of antibodies against PEG among patients with acute lymphoblastic leukemia (ALL) prior to and/or immediately after their first dose of pegylated E.coli asparaginase (PEG-ASNase). Serum samples of 701 children, 673 with primary ALL, 28 with relapsed ALL, and 188 adults with primary ALL were analyzed for anti-PEG IgG and IgM. Measurements in 58 healthy infants served as reference to define cut-points for antibody-positive and -negative samples. Anti-PEG antibodies were detected in ALL patients prior the first PEG-ASNase with a prevalence of 13.9% (anti-PEG IgG) and 29.1% (anti-PEG IgM). After administration of PEG-ASNase the prevalence of anti-PEG antibodies decreased to 4.2% for anti-PEG IgG and to 4.5% for anti-PEG IgM. Pre-existing anti-PEG antibodies did not inhibit PEG-ASNase activity but significantly reduced PEGASNase activity levels in a concentration dependent manner. Although pre-existing anti-PEG antibodies did not boost, pre-existing anti-PEG IgG were significantly associated with firstexposure hypersensitivity reactions (CTCAE grade 2) (p.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719085 | PMC |
| http://dx.doi.org/10.3324/haematol.2020.258525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.
BioDrugs
November 2024
Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Albert-Schweitzer-Campus 1, D-48149, Muenster, Germany.
Background: Pegunigalsidase alfa is a newly approved drug for the treatment of Fabry disease, designed to increase the plasma half-life and reduce immunogenicity of infused α-galactosidase A (AGAL). We provide the first comprehensive pharmacokinetic and immunogenic data apart from industry-initiated studies.
Methods: Pharmacokinetics of pegunigalsidase alfa, amino acid, and polyethylene glycol (PEG)-specific antibodies and immune complexes were measured in treated patients (11 switched, two naïve).
Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts.
ACS Nano
October 2024
Translational Bio-Nanosciences Laboratory, The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Article Synopsis
- Systemic use of nanomedicines activates the complement cascade, leading to immune responses that can affect their safety and effectiveness.
- Research found significant differences in complement activation levels by PEGylated liposomal doxorubicin (PLD) and dextran-coated superparamagnetic iron oxide nanoworms (SPIO NWs), highlighting that factors like age and specific antibodies play important roles in this activation.
- Anti-PEG IgM levels were identified as strong predictors of high complement activation with PLD, while the relationship with antidextran IgG and IgM for SPIO NWs was weaker, emphasizing the importance of immunoglobulins in complement interactions with nanoparticles.
Effect of Anti-PEG Antibody on Immune Response of mRNA-Loaded Lipid Nanoparticles.
Mol Pharm
November 2024
Laboratory of Drug and Gene Delivery Research, Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo 173-8605, Japan.
Lipid nanoparticle-encapsulated mRNA (mRNA-LNP) vaccines have been approved for use to combat coronavirus disease 2019 (COVID-19). The mRNA-LNPs contain PEG-conjugated lipids. Clinical studies have reported that mRNA-LNPs induce the production of anti-PEG antibodies, but the anti-PEG antibodies do not affect the production of neutralizing antibodies.
View Article and Find Full Text PDFLiposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies.
ACS Nano
August 2024
Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.
Article Synopsis
- The study explores how anti-PEG antibodies interact with PEGylated liposomal doxorubicin (PLD) and other liposomes, causing complement activation and drug release.
- Irinotecan liposomes (IL) and L-PLD, which have lower PEG content, showed less complement activation but still experienced destabilization by anti-PEG antibodies.
- Both anti-PEG IgG and IgM led to drug release and formation of different liposome structures, indicating that reducing PEG levels is not a reliable method to avoid destabilization by these antibodies in vivo.
Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults.
Allergy
September 2024
Harvard T.H. Chan School of Public Health, Harvard University, Cambridge, Massachusetts, USA.
Background: During the COVID-19 pandemic, novel nanoparticle-based mRNA vaccines were developed. A small number of individuals developed allergic reactions to these vaccines although the mechanisms remain undefined.
Methods: To understand COVID-19 vaccine-mediated allergic reactions, we enrolled 19 participants who developed allergic events within 2 h of vaccination and 13 controls, nonreactors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!